Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

1. Add a fibrate to a statin?

Add a fibrate to a statin? Add a fibrate to a statin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Add a fibrate to a statin? View/ Open Date 2010-10 Format Metadata Abstract Do not routinely add a fibrate to a statin for patients with type 2 diabetes who are at high risk for cardiovascular events. Strength

2019 PURLS

2. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. (PubMed)

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. BACKGROUND: Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages. METHODS: In this meta (...) -analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger

Full Text available with Trip Pro

2019 Lancet

3. Statins are of no benefit in acute respiratory distress syndrome

Statins are of no benefit in acute respiratory distress syndrome Signal - Statins are of no benefit in acute respiratory distress syndrome Dissemination Centre Discover Portal NIHR DC Discover Statins are of no benefit in acute respiratory distress syndrome Published on 13 March 2018 Giving statins to patients with acute respiratory distress syndrome made no difference to the number of days they spent on a ventilator. It also had no effect on mortality or the length of time spent in intensive (...) care or in hospital compared with placebo. In acute respiratory distress syndrome, the lungs become severely inflamed, fill with fluid (pulmonary oedema) and can no longer function. The person needs mechanical ventilation and is at high risk of multiple organ failure and mortality. This serious condition has high impact on both patients and NHS resources. Early studies had suggested statins may help to reverse the inflammatory process and could be a potential treatment to explore. This large

2019 NIHR Dissemination Centre

4. A statin drug during admission for heart surgery did not prevent an irregular heart beat

A statin drug during admission for heart surgery did not prevent an irregular heart beat Signal - A statin drug during admission for heart surgery did not prevent an irregular heart beat Dissemination Centre Discover Portal NIHR DC Discover A statin drug during admission for heart surgery did not prevent an irregular heart beat Published on 14 July 2016 The statin, rosuvastatin, taken by adults before and after heart surgery, did not prevent atrial fibrillation or heart muscle injury compared (...) was not shown to reduce atrial fibrillation, nor heart muscle damage. It did, as expected, reduce “bad” cholesterol and C-reactive protein, a marker of inflammation, compared to the inactive placebo. Statins do have proven longer term benefits in reducing further damage to the coronary arteries and deaths from heart disease. Share your views on the research. Why was this study needed? Atrial fibrillation can occur in about 20% of people undergoing heart surgery and if not corrected is associated with poorer

2019 NIHR Dissemination Centre

5. People take prescribed statins more reliably after discussing their advantages and disadvantages

People take prescribed statins more reliably after discussing their advantages and disadvantages People take prescribed statins more reliably after discussing their advantages and disadvantages Dissemination Centre Discover Portal NIHR DC Discover People take prescribed statins more reliably after discussing their advantages and disadvantages Published on 11 September 2018 doi: Patients want to know more about how statins work, the reasons for prescribing them and their possible side effects (...) . Statins lower cholesterol and reduce the risk of recurrent stroke or heart attack. They also help prevent cardiovascular disease developing in people at high risk. At a population, level statins reduce the overall incidence of cardiovascular disease for people at moderate risk, but the benefits for an individual are less clear-cut. This review found that people are happy to take statins if they believe they will prolong good quality of life. Barriers include mistrust and scepticism about over

2019 NIHR Dissemination Centre

6. On the history of statins

On the history of statins On the History of Statins – Clinical Correlations Search On the History of Statins January 11, 2019 By David Pineles, MD Peer Reviewed With the implementation of the ACC/AHA guidelines on assessment of cardiovascular risk, [1]. Dr. John Ioadnnidis, in an article published in JAMA in February 2014, estimated that under the new guidelines approximately 1 billion people worldwide would qualify to be prescribed a statin [2]. With such a large number of individuals taking (...) this medication, it begs the question: where did statins come from? The story begins with famous German pathologist Rudolf Virchow. In the mid-19th century, Virchow discovered that cholesterol was found in the arterial walls of individuals that died from vaso-occlusive diseases such as myocardial infarction [3]. In 1913, Russian pathologist Nikolai Anitschkow, the first person to describe foam cells [4], in a brilliant study, demonstrated cholesterol’s role in the development of atherosclerosis. He showed

2019 Clinical Correlations

7. Statins for the primary prevention of cardiovascular events

Statins for the primary prevention of cardiovascular events 2019 www.kce.fgov.be KCE REPORT 306 STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS 2019 www.kce.fgov.be KCE REPORT 306 HEALTH TECHNOLOGY ASSESSMENT STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS AUDREY CORDON, CHRISTOPHE DE MEESTER, SOPHIE GERKENS, DOMINIQUE ROBERFROID, CHRIS DE LAET COLOPHON Title: Statins for the primary prevention of cardiovascular events Authors: Audrey Cordon (KCE), Christophe De Meester (...) Générale), Christiaan Vrints (UZA – Universitair Ziekenhuis Antwerpen) External validators: Guy De Backer (Ugent), Oscar Franco (University of Bern), Bert Vaes (KULeuven) Reported interests: All experts and stakeholders consulted within this report were selected because of their involvement in the topic of ‘Statins’. Therefore, by definition, each of them might have a certain degree of conflict of interest to the main topic of this report. Membership of a stakeholder group on which the results

2019 Belgian Health Care Knowledge Centre

8. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association | Arteriosclerosis, Thrombosis, and Vascular Biology Search Hello Guest! Login to your account Email Password Keep me logged in Search Archive of all online content January 1, 1981 - January 1, 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Jump to Free Access article Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , MD, FAHA, Chair , FRCPath, PhD , MD, PhD, FAHA , MD, FAHA, Vice Chair , PharmD, MSPH, FAHA , MD, FAHA , MD , MD, FAHA , MD, FAHA , MD, MPH, FAHA , MD, FAHA , MD, FAHA , MD , PhD, FAHA , MD, PhD, FAHA Connie B. Newman , David Preiss , Jonathan A. Tobert , Terry A. Jacobson , Robert L. Page, II , Larry B. Goldstein , Clifford Chin , Lisa R

2019 American Gastroenterological Association Institute

9. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. (PubMed)

Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Background: Many guidelines use expected risk for cardiovascular disease (CVD) during the next 10 years as a basis for recommendations on use of statins for primary prevention of CVD. However, how harms were considered and weighed against benefits is often unclear. Objective: To identify the expected risk above which statins provide net benefit. Design (...) : Quantitative benefit-harm balance modeling study. Data Sources: Network meta-analysis of primary prevention trials, a preference survey, and selected observational studies. Target Population: Persons aged 40 to 75 years with no history of CVD. Time Horizon: 10 years. Perspective: Clinicians and guideline developers. Intervention: Low- or moderate-dose statin versus no statin. Outcome Measures: The 10-year risk for CVD at which statins provide at least a 60% probability of net benefit, with baseline risk

2018 Annals of Internal Medicine

10. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment 30420184 2018 11 13 1879-1913 2018 Oct 19 The American journal of cardiology Am. J. Cardiol. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. S0002-9149(18)31970-2 10.1016/j.amjcard.2018.09.041 High-dose statin (HDS) therapy is recommended to reduce (...) low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine) can lead to a higher proportion of high-risk patients achieving target LDL-C. A secondary objective was to assess the efficacy of triple

2018 EvidenceUpdates

11. Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. (PubMed)

Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Background: Many effects of statins on non-cardiovascular disease (non-CVD) outcomes have been reported. Purpose: To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes. Data Sources: MEDLINE and EMBASE (English terms only, inception to 28 May (...) 2018). Study Selection: Meta-analyses (published in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake. Data Extraction: Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify

2018 Annals of Internal Medicine

12. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. (PubMed)

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. BACKGROUND: Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or on statin therapy is uncertain. METHODS: Patient-level data from seven randomised, placebo-controlled (...) , statin outcomes trials were collated and harmonised to calculate hazard ratios (HRs) for cardiovascular events, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. HRs for cardiovascular events were estimated within each trial across predefined lipoprotein(a) groups (15 to <30 mg/dL, 30 to <50 mg/dL, and ≥50 mg/dL, vs <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis. FINDINGS: Analyses included data for 29 069

2018 Lancet

13. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial 30122341 2018 09 03 1097-685X 2018 Jul 21 The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial (...) . S0022-5223(18)31865-8 10.1016/j.jtcvs.2018.05.123 Statins prevent saphenous vein graft (SVG) disease and improve outcomes after coronary artery bypass graft surgery. However, the optimal postoperative statin dose remains unclear. The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events trial was undertaken to evaluate whether early postoperative high-dose statin therapy reduces SVG occlusion compared with conventional moderate-dose therapy. In this pilot, multicenter, double-blind randomized

2018 EvidenceUpdates

14. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. (PubMed)

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. OBJECTIVE: To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes. DESIGN: Retrospective cohort study. SETTING: Database of the Catalan primary care system (SIDIAP), Spain, 2006-15. PARTICIPANTS: 46 864 people aged (...) 75 years or more without clinically recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users. MAIN OUTCOME MEASURES: Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years

Full Text available with Trip Pro

2018 BMJ

15. Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins

Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins 30078477 2018 08 06 1879-1913 2018 Jul 04 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins. S0002-9149(18)31332-8 10.1016/j.amjcard.2018.06.040 Statins are usually well-tolerated drugs with a clear dose-dependent efficacy. However (...) , manifestation of statin's side effects also bears a direct relation to higher doses necessary to achieve high impact cholesterol-lowering effects. Nevertheless, the reliance on statin efficacy alone has often left dietary intervention underutilized even though studies have shown a reduction in serum cholesterol levels when dietary fiber intake is increased. In this meta-analysis, we investigated whether the concomitant use of psyllium, a gel-forming viscous soluble fiber, would cause further overall

2018 EvidenceUpdates

16. Statins and the risk of intracerebral haemorrhage inpatients with stroke: systematic review and meta-analysis

Statins and the risk of intracerebral haemorrhage inpatients with stroke: systematic review and meta-analysis 30150320 2018 08 28 1468-330X 2018 Aug 27 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Statins and the risk of intracerebral haemorrhage inpatients withstroke:systematic review and meta-analysis. jnnp-2018-318483 10.1136/jnnp-2018-318483 Whether statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke remains (...) uncertain. This study addresses the evidence of statin therapy on ICH and other clinical outcomes in patients with previous ischaemic stroke (IS) or ICH. A systematic literature review and meta-analysis was performed in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to assess observational and randomised studies comparing statin therapy with control (placebo or no treatment) in patients with a previous ICH or IS. The risk ratios (RR) for the primary

2018 EvidenceUpdates

17. Statin

Statin Top results for statin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for statin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

2018 Trip Latest and Greatest

18. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study

Association of statin use with spontaneous intracerebral hemorrhage: A cohort study 29970405 2018 07 31 1526-632X 91 5 2018 Jul 31 Neurology Neurology Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. e400-e409 10.1212/WNL.0000000000005907 To examine the association between statin exposure in a dose-dependent manner and intracerebral hemorrhage (ICH) in a large nationwide study. The computerized database of the largest health care provider in Israel was used (...) to identify diagnosed ICH among new users of statins, who started statin treatment between 2005 and 2010. We assessed a dose-response relationship between ICH and statins, using the average atorvastatin equivalent daily dose (AAEDD). Multivariable Cox proportional hazard regression models, adjusted for baseline disease risk score, were applied to estimate the hazard ratio of ICH. Of the 345,531 included patients, 1,304 were diagnosed with ICH during a median follow-up of 9.5 years (interquartile range 7.6

2018 EvidenceUpdates

19. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

20. Do statins prevent dementia?

Do statins prevent dementia? Do statins prevent dementia? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/06\/mo-june2018-pp54-55.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 25 2018 Do statins prevent dementia? By in , , , , Journal reference: McGuinness B, Craig D, Bullock R (...) , Passmore P. Statins for the prevention of dementia. Cochrane database of systematic reviews 2016 Jan 4(1):CD003160 Link: Published: January 2016 Evidence cookie says… Statins should not be used as a prophylaxis against dementia, as the only indication the limited evidence from high quality randomised trials suggests no effect there is some ambiguity as observational data has tended to suggest a protective effect The article was published in the June 2018 issue of Medical Observer , under the title

Full Text available with Trip Pro

2018 Morsels of Evidence